@article{51465dce664c47819ef1363a70f54802,
title = "Pathological findings in central nervous system demyelination associated with infliximab",
abstract = "Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.",
keywords = "Demyelination, central nervous system, infliximab, multiple sclerosis, neuropathology, rheumatoid arthritis, tumor necrosis factor (TNF) alpha inhibitors",
author = "Alicja Kalinowska-Lyszczarz and Mahboobeh Fereidan-Esfahani and Yong Guo and Lucchinetti, {Claudia F.} and Tobin, {W. Oliver}",
note = "Funding Information: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS. Demyelination central nervous system multiple sclerosis tumor necrosis factor (TNF) alpha inhibitors infliximab neuropathology rheumatoid arthritis Novartis https://doi.org/10.13039/100004336 CFTY720DUS37T National Institute of Neurological Disorders and Stroke https://doi.org/10.13039/100000065 R01 NS 49577-6 edited-state corrected-proof typesetter ts1 The authors acknowledge Patricia Ziemer for expert technical assistance with pathology. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from NIH R01 NS 49577-6 (C.F.L.) and Novartis CFTY720DUS37T (C.F.L.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Informed Consent Written informed consent was obtained from the patient according to the Declaration of Helsinki. ORCID iD W Oliver Tobin https://orcid.org/0000-0002-8141-2394 Publisher Copyright: {\textcopyright} The Author(s), 2019.",
year = "2020",
month = aug,
day = "1",
doi = "10.1177/1352458519894710",
language = "English (US)",
volume = "26",
pages = "1124--1129",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "9",
}